Best of AC2017 Session - Second-Line Therapy for Metastatic Renal Cell Carcinoma: Making Strategic Choices - On-Demand

    • List Price: $35.00
    • Member Price: $25.00

This session will explore new therapeutic options for the second-line treatment of metastatic renal cell carcinoma. As treatment options have expanded, the preferred second-line agent is being debated. Evidence for targeted therapies and immunotherapy in the second-line setting will be reviewed, with discussion of the advantages and disadvantages of therapy. This session will help the oncology pharmacist determine a strategy for selecting and recommending a second-line treatment option for a patient with metastatic renal cell carcinoma.


Content Area: Patient Management & Therapeutics

Product Details:

This session is from 2017 HOPA Annual Conference


Jocelyn Mohs, PharmD BCOP; Anne Spengler, PharmD BCOP; Rebecca Greene, PharmD BCOP


Learning Objectives:

1.      Identify controversies surrounding second-line therapy for metastatic renal cell carcinoma.


Show More
There are not any reviews for this product.
Contains 0 items
Subtotal: $0.00